Lyxumia Approval Status

  • FDA approved: No
  • Brand name: Lyxumia
  • Generic name: lixisenatide
  • Company: Sanofi
  • Treatment for: Diabetes, Type 2

Lyxumia (lixisenatide) is a once-daily prandial GLP-1 receptor agonist in development for the treatment of adults with type 2 diabetes mellitus.

FDA Approval Status for Lyxumia

DateArticle
Jun 14, 2014Sanofi's Lyxumia (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering than Liraglutide when Both were Added to Insulin Glargine
Sep 12, 2013Sanofi Provides Update on Lixisenatide New Drug Application in U.S.
Feb 19, 2013Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)